Xencor. has been granted a patent for untargeted and targeted IL-10-Fc fusion proteins, which include variants that bind to immune checkpoints such as PD-1 and TIGIT. The patent details specific amino acid substitutions for the IL-10 monomer domain to enhance its therapeutic potential. GlobalData’s report on Xencor gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Xencor, Personalized cancer vaccines was a key innovation area identified from patents. Xencor's grant share as of June 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Il-10-fc fusion proteins for targeted immune modulation
The granted patent US12006345B2 outlines a novel composition featuring a variant interleukin-10 (IL-10) monomer domain. This composition is characterized by specific amino acid substitutions made to a parent IL-10 monomer domain, which is defined by the sequences SEQ ID NO:3 or SEQ ID NO:4. The patent details a comprehensive list of potential substitutions, including individual changes such as N21D and D28N, as well as combinations of substitutions. The claims emphasize the flexibility in selecting these substitutions, allowing for a diverse range of variant IL-10 monomer domains that may be utilized in various applications.
In addition to the general claims regarding amino acid substitutions, the patent specifies several particular sequences (SEQ ID NO:562, SEQ ID NO:568, SEQ ID NO:571, SEQ ID NO:132, SEQ ID NO:139, SEQ ID NO:150, SEQ ID NO:171, SEQ ID NO:178, and SEQ ID NO:189) that can be incorporated into the variant IL-10 monomer domain. The claims also reiterate the potential for combinations of substitutions, further expanding the scope of the composition. This patent provides a detailed framework for the development of IL-10 variants, which may have significant implications for therapeutic applications, particularly in modulating immune responses.
To know more about GlobalData’s detailed insights on Xencor, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
